Prospective Observational Study of Once-Daily TamcontinÂ® Tablet (ContinusÂ® Controlled release tablet of Tamsulosin Hydrochloride, 0.4 mg) in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (BPH) in the Routine Clinical Practice

Prospective Observational Study to Assess the Safety and Efficacy of Once-Daily TamcontinÂ® Tablet (ContinusÂ® Controlled release tablet of Tamsulosin Hydrochloride, 0.4 mg) in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (BPH) in the Routine Clinical Practice

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2012/11/003151

Enrollment

100

Registered

2012-11-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Condition: Benign Prostate Hyperplasia (BPH)

Interventions

Intervention1: TamcontinÂ® tablet: TamcontinÂ® tablet (ContinusÂ® controlled release tablet of Tamsulosin hydrochloride, 0.4 mg)once a day for 6 weeks. Control Intervention1: Not Applicable: Not Appli

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed, treatment naive BPH patients eligible to receive Tamsulosin hydrochloride, 0.4 mg in the routine clinical practice

Exclusion criteria

Exclusion criteria: Not Applicable

Design outcomes

Primary

Measure	Time frame
To assess the safety and efficacy of once-daily TamcontinÂ® tablet (ContinusÂ® controlled release tablet of Tamsulosin hydrochloride, 0.4 mg) in the treatment of lower urinary tract symptoms secondary to Benign Prostatic Hyperplasia in the routine clinical practiceTimepoint: Patient Visits: Visit 1 (Day 0); Visit 2 (Week 3); and Visit 3 (Week 6)	—

Secondary

Measure	Time frame
Not ApplicableTimepoint: Not Applicable	—

Countries

India

Contacts

Public ContactDr Harbans Singh

R. G. Urology and Laparoscopy Hospital

harbanspruthi@hotmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026